



About Us





About Us

Leading the Evolution of Transdermal Absorption

It was over 40 years ago that we at Lead Chemical first turned our attention to transdermal absorption. As a result of continued study and repeated experiments over many years, we have developed proprietary formulation technology, and obtained Japan's first approval to manufacture and sell patches (nonsteroidal anti-inflammatory analgesic) that apply transdermal absorption technology. Since then, we have successfully changed the administration routes of oral medicines with excellent analgesic and anti-inflammatory effects to transdermal absorption, and have provided them to the front lines of medical care as medicines that are more beneficial for the patients. From local action to systemic drugs, to applications for a variety of disease areas, transdermal medicines continue to evolve. We will continue working to develop new medicines, leveraging the potential of transdermal absorption, to contribute both to the improvement of the quality of life (QOL) of patients struggling with diseases and to the progress of medical treatments.



Greetings

Medicines to relieve and treat the symptoms of diseases and injuries are essential for people to live in good health. However, the use of medicines is often associated with the discomfort of side effects. Lead Chemical succeeded in developing the first “transdermal absorption” patch in Japan. With the “transdermal absorption” technology, the active ingredient penetrates through the skin and acts directly on the affected area. This technology gave form to a medicine less likely to cause the unavoidable side effects accompanied by the use of oral medication such as gastrointestinal disorders.

Since its foundation, Lead Chemical has been consistently contributing to the improvement of patients' quality of life, as a pharmaceutical company specialized in transdermal absorption patches. Today, our products are sold not only in Japan, but also in many other countries.

We will continuously strive to respond to the demands for new transdermal absorption formulations worldwide. We are committed to fulfilling our mission and responsibilities as a pharmaceutical manufacturer, by delivering high-quality and safe pharmaceuticals to the world, and contributing to people's healthy and prosperous lives.



Tamaki Nakai,
President & CEO



Corporate philosophy

| Corporate philosophy

1. We strive to continuously create beneficial and reliable pharmaceutical products, and to supply products of superior quality, contributing to the health and well-being of people all over the world, across borders and respecting diversity.
2. We recognize that medicines are meant to protect people's lives and life-styles. As a company that produces medicines, our actions are based on high ethical standards and good social sense in order to preserve the global environment and to be in harmony with local communities.

| Compliance Code of Conduct

1. We will comply with laws and regulations and internal rules, and will act based on high ethical values and good social sense.
2. We will actively engage in social contribution activities in various ways, as bearers of the sound development of society.
3. We will practice proper transactions through fair and free competition.
4. We will care for the global environment, not only by observing the laws and regulations but also by promoting its conservation and improvement.
5. We will provide our customers with beneficial, reliable, high-quality pharmaceutical products, accompanied by accurate information.

| Quality policy

Under the following three pillars, Lead Chemical Co., Ltd. is committed to comply with laws and regulations with a customer's perspective in all corporate activities, ensuring stable supply of high-quality pharmaceutical products, and continuously improving the quality of our products and our quality system.

1. Compliance with laws and regulations
2. Supply of high-quality pharmaceutical products
3. Continuous improvement

Delivering High Quality
and Safe Medicines from Toyama to the World



Company Profile

Company name	Lead Chemical Co., Ltd.
Representative	Tamaki Nakai, PRESIDENT & CEO
Capital	JPY 458.67 million
Business establishments	<p>Head Office (Management Division) Ichigo Toyamaeki Nishi Bld. 2F, 1-1-19 Jinzuhonmachi, Toyama City, Toyama, 930-0008, JAPAN</p> <p>Research Center (Research & Development Division, Quality and Safety Management Division, Sales Division) Himata Plant 77-3 Himata, Toyama City, Toyama, 930-0912, JAPAN</p> <p>Hisagane Plant 327 Hisagane, Kamiichi-machi, Nakaniikawa-gun, Toyama, 930-0381, JAPAN</p>
Established	1969, June 23
Business contents	Manufacture and sales of pharmaceutical products
Main clients	Daiichi Sankyo Co., Ltd., DAIICHI SANKYO HEALTHCARE CO., LTD., Kaken Pharmaceutical Co., Ltd.

As of Nov 20, 2024





History

1969	Established with capital of JPY 5 million; started manufacture of first aid bandages
1972	Established the Hydrogel Patch Department
1979	Completed the GMP certified Himata Plant (Plant No.1)
1985	Completed the General Research Center
1988	Completed the Himata Plant (Plant No.2) Acquired marketing authorization for the medical transdermal absorption patch Adofeed® (the present Adofeed® Pap 40mg for prescription use)
1994	Completed the Hisagane Plant in Kamiichi Started export to Italy and South Africa (TransAct® LAT)
1995	Started exporting flurbiprofen to Europe
1998	Started export to Brazil (Targus® LAT)
2000	Started exporting menthol products to the United States
2006	Acquired manufacturing and marketing authorization for Loxonin® Pap 100mg (for prescription use) Expanded the Hisagane Plant
2008	Acquired marketing authorization for Loxonin® Tape 50mg and 100mg (for prescription use) Acquired marketing authorization for Adofeed® Pap 80mg
2011	Completed the Hisagane Plant (East Plant)
2015	Started export of Loxonin® Tape 50mg to China Acquired marketing authorization for Loxonin®S Pap, Loxonin®S Tape and Loxonin®S Tape L (behind-the-counter products)
2016	Ibuprofen Medicated Plaster approved for registration in 6 European countries
2017	Submitted application for registration of Loxonin® Pap in countries of the ASEAN region
2018	Started export of Ibuprofen Medicated Plaster for commercialization in Belgium, Ireland and UK Ibuprofen Medicated Plaster approved for registration in 16 additional European countries
2019	Ibuprofen Medicated Plaster was granted the “Product of the Year” award in UK, being the only OTC medicine to win the award in that year
2021	Completed the Research Center
2023	Completed the Hisagane Plant South (Packaging & Warehousing)

Offices

Head Office (Management Division)

Ichigo Toyamaeki Nishi Bld. 2F, 1-1-19 Jinzuhonmachi,
Toyama City, Toyama, 930-0008 JAPAN

TEL +81(76) 425-1973 / FAX +81(76) 423-8652



Research Center (Research & Development Division, Quality and Safety Management Division, Sales Division) Himata Plant

77-3 Himata, Toyama City,
Toyama, 930-0912, JAPAN

Research Center

TEL +81(76)413-3611 / FAX +81(76)413-3613

(Sales Division - International Business Department)

TEL +81(76) 464-5710 / FAX +81(76) 464-5730

(Sales Division - Domestic Business Department)

TEL +81(76) 424-2885 / FAX +81(76) 423-8652

Himata Plant

TEL +81(76)425-6828 / FAX +81(76)425-5429



Research Center



Himata Plant

Hisagane Plant

327 Hisagane, Kamiichi-machi, Nakaniikawa-gun, Toyama, 930-0381, JAPAN

TEL +81(76)472-5180 / FAX +81(76)472-5183



Hisagane Plant West



Hisagane Plant East



Hisagane Plant South
(Packaging & Warehousing)

